explore -WSS

explore

author：fashion 2025-09-29 16:35:24 - browse：9696

3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT — Adobe

Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： A new study asks: Are we harming blood donors by taking blood?

WSS

Inside the fall of star MIT scientist David Sabatini

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

Did the public have the right to know Arthur Ashe had AIDS?

7 people shot in DC, police say

A new study asks: Are we harming blood donors by taking blood?

Devoted Health’s losses in Medicare Advantage persist

entertainment

explore

explore

Apple is now the first public company to be valued at $3 trillion

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Jerome Adams on the need for new antivirals for Covid

PhRMA sues HHS over Medicare drug price negotiation

Apple is now the first public company to be valued at $3 trillion

Readout LOUD: Venture capital, Gilead, and more M&A

United colonoscopy coverage change 'may cost lives,' doctors say

The Biogen Aduhelm mess could happen again

Medical records are filled with copy

Cano Health’s bankruptcy is a warning for Medicare Advantage

hotspot

7 people shot in DC, police say

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

The Biogen Aduhelm mess could happen again

Listen: PBM conflicts, RSV vaccines, & the future of flu season

Updated Covid vaccine has 54% effectiveness, new study suggests

Bacterial infection may be ‘key event’ in endometriosis, study says

hotspot

hotspot

leisure time

explore